CSTL
Castle Biosciences IncKey Statistics
About Castle Biosciences Inc
Castle Biosciences Inc. is a pioneering company in the diagnostics sector, focused on transforming patient care through its innovative gene-expression profiling tests, particularly in skin cancer. Its leading product, DecisionDx®-Melanoma, plays a crucial role in the management of melanoma by providing vital insights into risk stratification and guiding treatment decisions based on gene expression analysis. Committed to advancing precision medicine, the company leverages its proprietary technology to develop additional assays that address significant clinical needs. With a strong emphasis on research and development and a promising pipeline, Castle Biosciences is well-positioned for sustainable growth while enhancing clinical outcomes and delivering value to shareholders in the dynamic oncology market.
Fundamentals
| Revenue (TTM) | $344.23M |
| Gross Profit (TTM) | $273.20M |
| EBITDA | $-2.04M |
| Operating Margin | -4.40% |
| Return on Equity | -5.21% |
| Return on Assets | -2.56% |
| Revenue/Share (TTM) | $11.88 |
| Book Value | $15.86 |
| Price-to-Book | 1.57 |
| Price-to-Sales (TTM) | 2.06 |
| EV/Revenue | 1.383 |
| EV/EBITDA | 41.96 |
| Quarterly Earnings Growth (YoY) | -51.60% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $30.30M |
| Float | $25.17M |
| % Insiders | 2.57% |
| % Institutions | 93.23% |
Historical Volatility
Volatility is currently contracting